Ertan Elif, Simsek Merve, Dogan Mustafa
Department of Ophthalmology, Health Sciences University Basaksehir Cam Sakura City Hospital, Istanbul, Türkiye.
Department of Ophthalmology, Mugla Training and Research Hospital, Mugla, Türkiye.
Beyoglu Eye J. 2025 Mar 25;10(1):20-24. doi: 10.14744/bej.2025.04695. eCollection 2025.
In our study, using amsterdam pre-operative anxiety and information scale (APAIS) and visual analog scale anxiety (VASA) analyze the patient's anxiety level about intraocular injection therapy and assess possible risk factors for these levels of anxiety in relation to the patient's sociodemographic, disease, and treatment characteristics.
Three hundred sixty-nine patients who received intravitreal ranibizumab, aflibercept, bevacizumab, and dexamethasone implants were included in the study. To measure the level of anxiety, APAIS questionnaire and VASA were used. APAIS and VASA were evaluated according to age, sex, indication for the injection, injection drug, previous injection numbers, and lens status in the study eye.
About 15.4% of the patients participating in the study had VASA ≥6. The APAIS anxiety component score of 43.9% of the patients was found to be ≥11. Total information requests were found to be ≥5 in 48.7% of the patients. There was a significant negative correlation between VASA, APAIS, and patient age (spearman r=-0.25, p=0.004, r=-0.22, p=0.001). A significant negative correlation was found between the number of previous injections and anxiety levels measured by VASA (spearman r=-0.35, p=0.02), as well as between the number of previous injections and APAIS scores (anxiety levels and total information request) (spearman r=-0.32, p=0.03). There was a no significant difference between VASA, APAIS, and patient sex (p<0.05). A higher level of anxiety measured by VASA and APAIS has been shown in patients who have not had cataract surgery before, compared to those who have undergone cataract surgery (p<0.05).
The study underscores the importance of improving patient information and conducting further research to alleviate stress levels.
在我们的研究中,使用阿姆斯特丹术前焦虑与信息量表(APAIS)和视觉模拟焦虑量表(VASA)分析患者对眼内注射治疗的焦虑水平,并评估与患者社会人口统计学、疾病和治疗特征相关的这些焦虑水平的可能风险因素。
纳入369例接受玻璃体内注射雷珠单抗、阿柏西普、贝伐单抗和地塞米松植入物的患者。使用APAIS问卷和VASA测量焦虑水平。在研究中,根据年龄、性别、注射指征、注射药物、既往注射次数和研究眼的晶状体状态对APAIS和VASA进行评估。
参与研究的患者中约15.4%的VASA≥6。发现43.9%的患者APAIS焦虑成分得分≥11。48.7%的患者总信息需求≥5。VASA、APAIS与患者年龄之间存在显著负相关(斯皮尔曼r=-0.25,p=0.004,r=-0.22,p=0.001)。既往注射次数与VASA测量的焦虑水平之间存在显著负相关(斯皮尔曼r=-0.35,p=0.02),既往注射次数与APAIS评分(焦虑水平和总信息需求)之间也存在显著负相关(斯皮尔曼r=-0.32,p=0.03)。VASA、APAIS与患者性别之间无显著差异(p<0.05)。与接受过白内障手术的患者相比,未接受过白内障手术的患者中,VASA和APAIS测量的焦虑水平更高(p<0.05)。
该研究强调了改善患者信息以及开展进一步研究以减轻压力水平的重要性。